WST

West Pharmaceutical Services (United States)

$417.80

+0.33%
Nov 16, 2026
Bobby Quantitative Model
West Pharmaceutical Services is a Pennsylvania-based supplier of elastomer-based packaging components (stoppers, seals, plungers), non-glass containment solutions, and self-injection delivery devices to pharmaceutical, biotechnology, and generic drug manufacturers, operating in the Medical Instruments & Supplies industry with roughly 80% of revenue from proprietary products and 20% from contract manufacturing. The company occupies a high-moat, mission-critical niche in the injectable drug supply chain, functioning as a picks-and-shovels enabler for biologics, peptides, and small-molecule therapies rather than a drug developer itself, with approximately 55% of revenue generated internationally. The current investor narrative centers on West as a structural beneficiary of GLP-1 receptor agonist demand, a theme management explicitly cited when it raised full-year guidance after a strong Q1, and on the margin recovery now visible in recent quarters as high-value proprietary products and self-injection devices scale. Debate has shifted from 2024-era destocking and bioprocessing headwinds toward the durability of the growth reacceleration, the sustainability of the gross-margin climb back toward 40%, and whether the stock's premium multiple is justified after a 56% one-year run that has decisively outpaced the broader healthcare tape.

People also watch

Intuitive Surgical

Intuitive Surgical

ISRG

Analysis
Becton Dickinson

Becton Dickinson

BDX

Analysis
ResMed

ResMed

RMD

Analysis
Modernland Realty Ltd

Modernland Realty Ltd

MDLN

Analysis
Solventum

Solventum

SOLV

Analysis

BobbyInvestment Opinion: Should I buy WST Today?

Rating: Buy, with valuation discipline. The thesis is that West is a high-moat, essentially debt-free compounder (debt-to-equity 0.131) whose margin inflection is real and still early — Q3 2026 gross margin of 39.73% and operating margin of 30.58% versus 36.49% and 21.60% a year earlier — and that the 15-Buy/0-Hold/1-Sell consensus with a $471.00 average target (13.1% upside from $416.42) reflects directionally correct conviction even if the magnitude is debated. The core reasoning: earnings power is inflecting faster than the multiple is expanding, so the stock is growing into its valuation rather than relying on re-rating.

Supporting evidence is concrete. First, valuation versus history: 40.28x trailing and 40.07x forward PE sit in the lower-middle of West's own 30x-63x band and well below the 45x-63x of 2023-2024, while the 6.47x PS is near the low end of its historical range. Second, growth trajectory: revenue rose from $698.2 million in Q1 2025 to $874.5 million in Q3 2026, roughly 25% cumulative over six quarters, with three consecutive quarters above $840 million and 8.73% year-over-year growth in the latest quarter. Third, profitability: net income nearly doubled year-over-year to $214.0 million (24.47% net margin versus 17.41%), with gross margin climbing sequentially 35.08% → 37.74% → 39.73%. Fourth, cash: TTM free cash flow of $453.4 million covers $39.1 million of quarterly capex and a $15.5 million dividend, and $231.0 million of Q3 buybacks were funded internally. The offset is that the 33.99 PEG and a roughly 60-70% earnings-multiple premium to medical-instruments peers in the low-to-mid 20s mean the market is paying up for that quality.

Three risks could invalidate the thesis: (1) gross margin stalling near 40% rather than reaching the low-40s, which would compress the premium multiple toward peers; (2) GLP-1 ordering deceleration or renewed customer destocking, which would hit the ~83% proprietary-product mix ($728.8 million of $874.5 million) directly; and (3) the stock's technical extension — at $416.42 it sits at ~89.9% of the $223.83-$438.27 range after a 56.16% one-year run, with a beta of 1.139 amplifying any risk-off rotation. The rating would upgrade to a stronger Buy if the PE compresses below ~35x while gross margin holds above 40%, or if the average target rises toward the $500 high on a guidance raise; it would downgrade to Hold if gross margin fails to exceed 40% by Q1 2027, if revenue growth decelerates below ~5%, or if the stock breaks below the $390-$400 support zone on volume. Verdict: fairly valued to modestly undervalued relative to its own history, but at a clear premium to peers — a quality-at-a-fair-price call rather than a bargain.

Sign up to view all

WST 12-Month Price Forecast

The forward view is constructive but not euphoric. West's earnings power is inflecting faster than its multiple — 40.28x trailing PE sits in the lower-middle of its own 30x-63x band despite a 56% one-year rally — and the margin path (35.08% → 37.74% → 39.73% gross) plus three quarters of revenue above $840 million support a base case of roughly $440-$471 over 12 months. The main constraint is price: a 33.99 PEG and a 60-70% earnings-multiple premium to peers mean the stock is priced for continued margin expansion, and the wide $340-$500 target spread confirms analysts agree on direction but not magnitude. I would upgrade to high confidence if gross margin clears 40% in the next two quarters with revenue growth holding near 9%, and I would downgrade to neutral if margin stalls near 40%, revenue growth slips below 5%, or the stock breaks the $390-$400 support zone.

Historical Price
Current Price $417.80
Average Target $455.50
High Target $500.00
Low Target $340.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on West Pharmaceutical Services (United States)'s 12-month outlook, with a consensus price target around $471.00 and implied upside of +12.7% versus the current price.

Average Target

$471.00

16 analysts

Implied Upside

+12.7%

vs. current price

Analyst Count

16

covering this stock

Price Range

$340 - $500

Analyst target range

Buy
15 (94%)
Hold
0 (0%)
Sell
1 (6%)

Coverage is robust with 15 analysts, and sentiment is overwhelmingly bullish: 15 Buy ratings, zero Holds, and one Sell produce a consensus recommendation of strong_buy with a recommendation mean of 1.375. The average target price of $471.00 implies roughly 13.1% upside from the current $416.42, a meaningful but not extreme gap that suggests the Street sees further room without pricing in a dramatic re-rating. The consensus leans clearly bullish, and the absence of Hold ratings indicates high conviction in the GLP-1 and margin-recovery thesis, though the single Sell is a reminder that valuation skeptics exist. The target range of $340.00 to $500.00 is wide, spanning about 38% of the current price, which signals genuine disagreement about the growth trajectory rather than a tightly clustered consensus. The $500 high target likely assumes continued gross-margin expansion toward the low-40s, sustained GLP-1-driven volume growth, and multiple maintenance or modest expansion on a $14.45 consensus EPS base; the $340 low target implies roughly 18% downside and likely prices in margin compression, slower peptide demand, or multiple contraction toward the low end of the historical band. Institutional ratings show a constructive pattern: Morgan Stanley upgraded to Overweight from Equal Weight on September 22, 2026, and Citigroup, Evercore ISI, TD Cowen, Barclays, and UBS have all reiterated Buy or Outperform ratings through late October, with no downgrades in the visible record. The clustering of reiterations immediately after the October 29 earnings report suggests the Q3 beat and margin expansion validated the bull case, and the wide target spread combined with near-unanimous Buy ratings implies analysts are confident in direction but divided on magnitude.

Drowning in data?

Find the real signal!

Bulls vs Bears: WST Investment Factors

The bull case currently holds the stronger evidence: the margin inflection is measurable and accelerating (gross margin up 465 basis points year-over-year to 39.73%, operating margin up nearly 900 basis points to 30.58%), revenue has reaccelerated for three straight quarters, and the balance sheet carries essentially no leverage at 0.131 debt-to-equity. Analyst sentiment is near-unanimous at 15 Buy versus one Sell with a $471 average target implying 13.1% upside, and the 40.28x PE sits in the lower-middle of West's own historical band despite the 56% one-year run. The bears' strongest argument is not fundamentals but price: a 33.99 PEG ratio and a 60-70% earnings-multiple premium to peers mean the stock is priced for continued margin expansion and GLP-1 volume growth with little tolerance for slippage. The single most important tension is whether the gross-margin climb toward the low-40s proves structural (proprietary mix and self-injection scale) or cyclical (recovery off a depressed 2024-2025 base) — if margins stall near 40%, the premium multiple compresses and the wide $340-$500 target spread resolves toward the low end.

Bullish

  • Margin inflection is dramatic and accelerating: Gross margin climbed from 35.08% in Q1 to 37.74% in Q2 to 39.73% in Q3 2026, while operating margin jumped from 21.60% in Q3 2025 to 30.58% in Q3 2026. Net income nearly doubled year-over-year to $214.0 million, lifting net margin from 17.41% to 24.47%. This is a genuine operating-leverage story, not a one-off.
  • Revenue reaccelerating on GLP-1 demand: Q3 2026 revenue of $874.5 million grew 8.73% year-over-year and marked the third consecutive quarter above $840 million after the $805.0 million Q4 2025 trough. Cumulative revenue growth of roughly 25% from Q1 2025's $698.2 million confirms a durable recovery, and management explicitly raised full-year guidance citing GLP-1-driven demand.
  • Fortress balance sheet funds growth and buybacks: Debt-to-equity of 0.131, a current ratio of 3.02, and $464.1 million of cash leave essentially no financial risk. TTM free cash flow of $453.4 million comfortably covers $39.1 million of quarterly capex and the $15.5 million dividend, while $231.0 million of Q3 buybacks signal management confidence in the cash-generation runway.
  • Near-unanimous analyst conviction: All 15 covering analysts are constructive: 15 Buy, zero Hold, one Sell, for a strong_buy consensus and a 1.375 recommendation mean. The $471.00 average target implies 13.1% upside from $416.42, and the clustering of Buy reiterations from Morgan Stanley, Citigroup, Evercore ISI, TD Cowen, Barclays, and UBS after the October 29 report suggests the Q3 beat validated the bull case.

Bearish

  • Premium multiple demands flawless execution: The 40.28x trailing PE and 6.47x PS represent a roughly 60-70% premium to typical medical-instruments multiples in the low-to-mid 20s on earnings. The 33.99 PEG ratio is a red flag that growth is priced at a steep premium to its rate, leaving little room for disappointment.
  • Growth rate does not justify the multiple: Revenue growth of 8.73% year-over-year is solid but mid-single-digit territory, and the flat 40.28x trailing versus 40.07x forward PE implies the market expects essentially no near-term earnings acceleration. If growth normalizes toward high-single digits, the historical valuation band itself could compress.
  • Stock is extended and near resistance: At $416.42, shares sit at roughly 89.9% of the $223.83-$438.27 52-week range, within about 5% of the high, after gains of 56.16% over one year and 50.66% YTD. The 24.83% max drawdown shows the trend has not been linear, and the November 5 gap to $392.48 hints at distribution risk below the $390-$400 support zone.
  • Wide target spread signals real disagreement: The $340.00-$500.00 analyst range spans about 38% of the current price, and the lone Sell rating is a reminder that valuation skeptics exist. The $340 low target implies roughly 18% downside and likely prices in margin compression or slower peptide demand, undercutting the appearance of consensus.

WST Technical Analysis

West Pharmaceutical is in a sustained, powerful uptrend: shares are up 56.16% over the past year and 50.66% year-to-date, and at $416.42 the stock sits at roughly 89.9% of its 52-week range of $223.83 to $438.27. That positioning near the top of the range confirms momentum leadership rather than a value setup, though it also means the stock is approaching a well-defined resistance ceiling with limited overhead price discovery. The 24.83% max drawdown over the trailing period shows the trend has not been linear, but the recovery has been forceful enough to leave the stock within about 5% of its high. Short-term momentum is accelerating rather than fading: the stock gained 11.15% over the past month and 19.17% over three months, with the one-month move actually outpacing the three-month pace, a hallmark of trend re-acceleration. This is a striking divergence from the market, with relative strength of +13.41 percentage points versus SPY over one month and +43.89 points over one year, while SPY itself fell 2.26% and 2.83% over the one- and three-month windows. The 37.48% six-month gain and +35.35-point relative strength confirm the move is broad-based rather than a single-week spike, though the absence of volume data and RSI in the provided dataset limits confirmation of whether the latest leg is overbought. Key technical support sits at the 52-week low of $223.83, with the more relevant near-term floor likely in the $390-$400 zone where the stock consolidated in late October; resistance is the 52-week high of $438.27, roughly 5.2% above the current price. A breakout above $438.27 would signal the market is validating the GLP-1 growth and margin-recovery thesis with fresh capital and could open a new leg higher, whereas a breakdown below $390 would suggest the November 5 gap lower to $392.48 was the start of distribution rather than a shakeout. With a beta of 1.139, West is about 14% more volatile than the market, meaning position sizing should account for modestly amplified drawdowns, and the 2.91 short ratio indicates short interest is not a meaningful contrarian catalyst in either direction.

Beta

1.14

1.14x market volatility

Max Drawdown

-24.8%

Largest decline past year

52-Week Range

$224-$438

Price range past year

Annual Return

+59.9%

Cumulative gain past year

PeriodWST ReturnS&P 500
1m+8.8%-3.0%
3m+20.5%-3.6%
6m+36.8%-0.2%
1y+59.9%+10.1%
ytd+51.2%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

WST Fundamental Analysis

Revenue is reaccelerating on a sequential and year-over-year basis: Q3 2026 revenue of $874.5 million grew 8.73% year-over-year versus $804.3 million in Q3 2025, and rose from $844.9 million in Q1 and $872.3 million in Q2, marking a third consecutive quarter above $840 million after the $805.0 million trough in Q4 2025. The proprietary products segment generated $728.8 million, or roughly 83% of quarterly revenue, confirming that the high-value containment and self-injection franchise is the growth engine while contract manufacturing remains the smaller drag-free contributor. The trajectory from $698.2 million in Q1 2025 to $874.5 million in Q3 2026 represents roughly 25% cumulative growth over six quarters, consistent with management's GLP-1-driven guidance raise and supportive of a durable mid-to-high-single-digit organic growth story. Profitability is inflecting sharply: Q3 2026 net income reached $214.0 million on a 24.47% net margin, up from $140.0 million and a 17.41% margin in Q3 2025, while gross margin expanded from 36.49% to 39.73% over the same span and operating margin jumped from 21.60% to 30.58%. The sequential gross-margin path of 35.08% in Q1, 37.74% in Q2, and 39.73% in Q3 shows a clear, accelerating expansion driven by proprietary-product mix and operating leverage, with the 20.09% trailing operating margin and 35.89% gross margin in the valuation dataset reflecting the lagging twelve-month average rather than the current run-rate. At a 24.47% net margin, West is now operating well above typical medical-supplies profitability and closer to the high-margin tool-and-component model that historically justified its premium. The balance sheet is fortress-like: debt-to-equity of just 0.131, a current ratio of 3.02, and $464.1 million of cash at the end of Q3 against minimal interest expense, giving the company ample internal funding capacity. Free cash flow of $150.4 million in Q3 and $453.4 million TTM comfortably covers $39.1 million of quarterly capex and the $15.5 million dividend, while the company repurchased $231.0 million of stock in Q3, signaling confidence in the cash-generation runway. ROE of 15.54% and ROA of 11.89% are solid though flattered by a low equity base from buybacks, and the 0.13 debt-to-equity ratio means financial risk is negligible; the main capital-allocation question is whether buybacks at current valuations are the best use of cash versus capacity expansion for GLP-1 demand.

Quarterly Revenue

$874500000.0B

2026-09

Revenue YoY Growth

+8.7%

YoY Comparison

Gross Margin

39.7%

Latest Quarter

Free Cash Flow

$453400000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Proprietary Products

Open an Account, get $2 TSLA now!

Valuation Analysis: Is WST Overvalued?

Because West is solidly profitable with positive net income, the PE ratio is the appropriate primary metric: the stock trades at 40.28x trailing earnings and 40.07x forward earnings, an unusually narrow gap that implies the market expects essentially no near-term earnings acceleration beyond what is already discounted. That flat trailing-to-forward relationship is notable given the Q3 EPS of $3.04 annualizes to roughly $12 and the consensus 2027 EPS estimate of $14.45, suggesting the forward multiple may be conservative if margin expansion continues. On the secondary metrics, the 6.47x PS ratio and 8.50x EV/sales look rich in absolute terms but are more meaningful against the company's 24.47% net margin and 35.89% gross margin. Against the industry, West's 40.28x trailing PE and 6.47x PS represent a substantial premium to typical medical-instruments-and-supplies multiples, which generally run in the low-to-mid 20s on earnings; the roughly 60-70% earnings-multiple premium is justified only if the 8.73% revenue growth and 39.73% gross margin prove durable and expandable. The 25.33x EV/EBITDA and 26.35x price-to-cash-flow multiples reinforce that investors are paying for quality and growth rather than current cash returns, and the 33.99 PEG ratio is a red flag that growth is being priced at a steep premium to its rate. Historically, West's PE has ranged from roughly 30x to 63x over the past several years, with the current 40.28x sitting in the lower-middle of that band and well below the 45-63x levels seen in 2023-2024, while the PS ratio of 6.47x is near the low end of its historical 20x-48x range. That combination suggests the stock is not expensive relative to its own history even after the 56% rally, because earnings and revenue have grown into the multiple; the risk is that the historical band itself compresses if growth normalizes toward high-single digits.

PE

40.3x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 30x~59x

vs. Industry Avg

40.3x

Industry PE ~40.3x*

EV/EBITDA

25.3x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks are modest but not absent. The company carries debt-to-equity of just 0.131 and a current ratio of 3.02, so balance-sheet stress is negligible; the real financial risk is earnings quality dependent on continued margin expansion, with Q3 2026 net income of $214.0 million representing a 24.47% margin that is far above the 17.41% earned a year earlier and the 16.06% trailing twelve-month figure. Roughly 83% of quarterly revenue ($728.8 million of $874.5 million) comes from proprietary products, creating concentration in the injectable-drug supply chain and in GLP-1-adjacent demand; a slowdown in peptide volumes or customer destocking, as seen in the 2024-era headwinds, would hit the highest-margin line directly. Capital allocation is a secondary risk: $231.0 million of Q3 buybacks at a 40x multiple may prove less accretive than capacity expansion if GLP-1 demand outruns supply, and the 33.99 PEG ratio means any earnings miss is punished disproportionately. Market and competitive risks center on valuation compression. At 40.28x trailing and 40.07x forward earnings, West trades at a 60-70% premium to medical-instruments peers in the low-to-mid 20s, and the 25.33x EV/EBITDA and 26.35x price-to-cash-flow multiples show investors are paying for quality rather than current cash returns. A beta of 1.139 means the stock is about 14% more volatile than the market, so rotation out of premium healthcare names or a rise in real rates would amplify downside; the 56.16% one-year gain and 43.89-point relative strength versus SPY leave the stock crowded and momentum-dependent. Competitive threats include alternate containment formats and pricing pressure from large pharma customers, while the wide $340-$500 analyst target range spanning 38% of the current price confirms genuine disagreement about the growth trajectory rather than a tightly clustered consensus. The worst-case scenario is a chain in which GLP-1 ordering decelerates, gross margin stalls near 40% instead of reaching the low-40s, and the multiple compresses toward the peer-group low-to-mid 20s on earnings. That combination would take the stock toward the $340 analyst low target, roughly 18% below the current $416.42, and a deeper de-rating toward the 52-week low of $223.83 would represent about 46% downside. The 24.83% trailing max drawdown is a realistic guide to a single adverse cycle, meaning an investor could lose roughly a quarter of capital in a margin-disappointment scenario before any recovery, with the November 5 gap to $392.48 marking the first technical warning level.

FAQ

Ranked by severity: first, valuation compression — at 40.28x trailing PE versus peer multiples in the low-to-mid 20s, a de-rating alone could erase a third of the price even with flat earnings, and the 33.99 PEG leaves no cushion for a miss. Second, revenue concentration and GLP-1 dependence — proprietary products were $728.8 million of $874.5 million in Q3 2026 (~83%), so any peptide ordering slowdown or customer destocking, as seen in 2024, hits the highest-margin line directly; the CooperCompanies destocking-driven 16% after-hours drop is a live sector reminder. Third, margin-execution risk — the gross-margin climb from 35.08% to 39.73% over three quarters must continue toward the low-40s; a stall near 40% would undercut the entire premium-multiple thesis. Fourth, market sensitivity — a beta of 1.139 makes the stock about 14% more volatile than the index, and with the shares up 56.16% over one year and 50.66% YTD, a rotation out of crowded premium healthcare names would amplify drawdowns; the 24.83% max drawdown shows a realistic single-cycle loss of roughly a quarter of capital.

The scenario framework assigns a 58% probability to the base case of $440-$471, a 22% probability to the bull case of $471-$500, and a 20% probability to the bear case of $340-$392. The base case assumes high-single-digit revenue growth near the Q3 8.73% rate, gross margin holding at or above 39.73% and grinding toward 40-41%, and a forward PE near 40x, converging on the $471.00 average target — about 13% upside from $416.42. The bull case requires gross margin pushing into the low-40s as self-injection devices scale, with the Street migrating toward the $500 high target on another guidance raise. The bear case envisions GLP-1 destocking and a multiple compression toward peer levels, retesting $390-$400 and potentially the $340 low target. The base case is most likely because it requires only continuation of the current trajectory rather than acceleration; the key assumption is that no customer inventory correction interrupts the margin climb.

The answer depends on the benchmark. Against its own history, WST looks fairly valued to modestly undervalued: 40.28x trailing and 40.07x forward PE sit in the lower-middle of its 30x-63x historical band and well below the 45x-63x of 2023-2024, while the 6.47x PS ratio is near the low end of its range — earnings and revenue have grown into the multiple. Against peers, it is clearly expensive: medical-instruments companies typically trade in the low-to-mid 20s on earnings, so WST carries a roughly 60-70% premium, reinforced by 25.33x EV/EBITDA and 26.35x price-to-cash-flow. The near-identical trailing and forward multiples imply the market expects no near-term earnings acceleration beyond the $14.45 consensus, which may prove conservative if margins keep climbing. The market is paying for durability and margin expansion, not for current cash returns — the 33.99 PEG is the clearest signal that growth is priced richly relative to its rate.

From a risk/reward standpoint, WST offers roughly 13.1% upside to the $471.00 average analyst target against about 18% downside to the $340.00 low target — a moderately favorable but not asymmetric setup. The fundamental case is strong: Q3 2026 gross margin of 39.73% is up 465 basis points year-over-year, operating margin of 30.58% nearly doubled from 21.60%, and net income of $214.0 million lifted net margin to 24.47% from 17.41%. The balance sheet removes financial risk entirely (debt-to-equity 0.131, current ratio 3.02), and 15 of 16 analysts rate it Buy. The catch is price: at 40.28x trailing earnings and a 33.99 PEG, the stock already discounts continued margin expansion, and it sits within about 5% of its $438.27 52-week high after a 56.16% one-year gain. It is a good buy for long-horizon investors comfortable with a 1.139 beta and willing to accumulate on pullbacks toward the $390-$400 support zone; it is a poor entry for anyone expecting a quick re-rating from here.

WST is fundamentally a long-term holding. It is a mid-stage compounder with visible earnings growth (Q3 2026 EPS of $3.04 versus $1.94 a year earlier), a fortress balance sheet, and a structural demand driver in GLP-1 and biologics fill-finish that plays out over years, not quarters. The low dividend yield of 0.31% and 12.4% payout ratio mean total return depends on earnings growth and multiple stability, which favors patient capital. Short-term trading is disadvantaged by the 1.139 beta, the 24.83% max drawdown, and the stock's position at ~89.9% of its 52-week range after a 56.16% run — momentum can reverse sharply, as the November 5 drop to $392.48 showed. A minimum holding period of 18-24 months is appropriate, long enough to span at least two more earnings cycles and confirm whether gross margin sustainably clears 40%; traders should instead wait for a retest of the $390-$400 support zone before establishing positions.